SEP
LKFT

Signature Equity Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Signature Equity Partners’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$690 Hold
23
– – ﹤0.01% 1382
2026
Q1 		$690 Buy
23
+1
+5% +$33 ﹤0.01% 1331
2025
Q4 		$719 Buy
+22
New +$710 ﹤0.01% 1473

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
DO
denkapparat Operations Berlin, Germany $306M AUM 40.46% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Signature Equity Partners's LKFT Position: Q2 2026 in Review

Signature Equity Partners held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q2 2026 at 23 shares worth $690. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

Signature Equity Partners first reported a position in LKFT in Q4 2025 and has held it in 3 quarters since. The position peaked at $719 in Q4 2025. 24 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Signature Equity Partners held 23 shares of Lakefront Biotherapeutics American Depositary Shares worth $690 as of Q2 2026.
  • Signature Equity Partners left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q2 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1382 holding.
  • Signature Equity Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $719 in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.